Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16)
Sign Up to like & getrecommendations! Published in 2022 at "Gastric Cancer"
DOI: 10.1007/s10120-021-01276-4
Abstract: A subgroup analysis of data from a nationwide study (KCSG-ST19-16) was performed to evaluate the efficacy and safety of second-line ramucirumab plus paclitaxel treatment in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced… read more here.
Keywords: second line; plus paclitaxel; ramucirumab plus; treatment ... See more keywords
Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer
Sign Up to like & getrecommendations! Published in 2018 at "International Journal of Clinical Oncology"
DOI: 10.1007/s10147-018-01391-w
Abstract: BackgroundDose modification of chemotherapy for metastatic colorectal cancer (MCRC) is often needed, especially in second-line and later-line treatments due to adverse events of previous treatment and poor patient condition. No study has focused on ramucirumab… read more here.
Keywords: metastatic colorectal; folfiri; plus modified; line ... See more keywords
P1-347Actual clinical use of Ramucirumab plus Paclitaxel at our hospital
Sign Up to like & getrecommendations! Published in 2017 at "Annals of Oncology"
DOI: 10.1093/annonc/mdx621.038
Abstract: Results: The median follow-up was 13.7 months (range: 3.1-25.2 months). The median age was 70 years (range: 56-82 years), and 5 patients were male. The primary sites of mucosal malignant melanoma were head and neck… read more here.
Keywords: plus paclitaxel; clinical use; 347actual clinical; use ramucirumab ... See more keywords
Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)
Sign Up to like & getrecommendations! Published in 2021 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/17588359211042812
Abstract: Background: Ramucirumab as monotherapy or in combination with paclitaxel is a second-line treatment option recommended for patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. However, real-world data from large study… read more here.
Keywords: plus paclitaxel; real world; line; treatment ... See more keywords
Clinical Implication of Liver Metastasis in the Treatment of Gastric Cancer
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Gastric Cancer"
DOI: 10.5230/jgc.2023.23.e21
Abstract: The RAINBOW study is a phase 3 trial comparing the combination therapy of ramucirumab plus paclitaxel with paclitaxel monotherapy as palliative second-line treatment in patients with gastric or gastroesophageal junction adenocarcinoma [1]. A significant increase… read more here.
Keywords: liver metastasis; gastric cancer; treatment; cancer ... See more keywords